Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22394216 | 0.89 | MGLL (0.70) | MGLLCHRM2CHRM3 | |
| SCHEMBL17611770 | 0.87 | CHRM2 (0.69) | MGLLCHRM2CHRM3CYP2D6OPRM1 | |
| SCHEMBL26552039 | 0.86 | MGLL (0.60) | MGLLCHRM2CHRM3CYP2D6CYP3A4 | |
| SCHEMBL17318938 | 0.84 | MGLL (0.51) | MGLLCHRM2CHRM3CYP2D6CYP3A4 | |
| SCHEMBL17324842 | 0.84 | MGLL (0.70) | MGLLCHRM2CHRM3CYP2D6CYP3A4 | |
| SCHEMBL21254493 | 0.83 | MGLL (0.58) | MGLLCHRM2CHRM3CYP2D6CYP3A4 | |
| SCHEMBL20397155 | 0.83 | MGLL (1.00) | MGLLCHRM2CHRM3CYP2D6CYP3A4 | |
| SCHEMBL18719631 | 0.82 | MGLL (0.58) | MGLLCHRM2CHRM3CYP2D6OPRM1 | |
| SCHEMBL21254504 | 0.82 | MGLL (0.57) | MGLLCHRM2CHRM3CYP2D6CYP3A4 | |
| SCHEMBL20411485 | 0.81 | MGLL (1.00) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | PFIZER INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190292203-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2019-09-26 | — | — | US | disclosed |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER (US) | 2018-07-26 | — | — | US | disclosed |
| WO-2018134698-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| EP-3149007-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015185207-A1 | ALKYL AND ARYL DERIVATIVES OF 1-OXA-4,9-DIAZASPIRO UNDECANE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292203-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | MAG, MAGI3, APC | MGLL 16/4885CHRM2 4353/4885CHRM3 4324/4885 |
| US-20180208608-A1 | HETEROCYCLIC SPIRO COMPOUNDS AS MAGL INHIBITORS | MAG, MAGI3, APC | MGLL 16/4885CHRM2 4353/4885CHRM3 4324/4885 |
| US-10858373-B2 | Heterocyclic spiro compounds as MAGL inhibitors | MAG, MAGI3, APC | MGLL 16/4885CHRM2 4353/4885CHRM3 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.